Martha J Morrell, MD
Neurology · Stanford
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- 17
- 3 carriers
- Office
- 1
Offices
1 location · Stanford Health Care · 3,152 clinicians in this group
Looking this up.
Hospitals listed: Stanford Health Care. That is not proof they admit you there this week.
Plans that list them
17 plans · 3 carriers
A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Dr. Morrell’s office at (650) 723-4000 to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.
17 of 17 plans
| Alignment Health BreathEasy (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Clarity (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Harmony (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes CalPlus (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes Care (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Heart & Diabetes Choice (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Honor+ Plan (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health My Choice CalCare (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Silicon (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health smartHMO (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health the ONE (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| SCAN Balance (HMO C-SNP) | SCAN Health Plan | Listed | Oct 3, 2026 |
| SCAN Classic (HMO) | SCAN Health Plan | Listed | Oct 3, 2026 |
| SCAN MyChoice (HMO) | SCAN Health Plan | Listed | Oct 3, 2026 |
| SCAN Strive (HMO C-SNP) | SCAN Health Plan | Listed | Oct 3, 2026 |
| DualConnect (HMO D-SNP) | Santa Clara Family Health Plan | Listed | Sep 1, 2026 |
Hospitals they work in
1 hospital
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- Stanford Health CareStanford, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency departmentPart of Stanford Health Care, which runs 3 hospitalsHome of Stanford Cancer Institute, a National Cancer Institute designated comprehensive cancer centrePatients rate it 4 of 5 · 83% would definitely recommend itOverall rating: 5 of 5 starsWorse than the national rate — Perioperative pulmonary embolism or deep vein thrombosis rate: 5.31 (4.24 to 6.37) · 8,661 cases, Jul 2022 – Jun 2024Worse than the national rate — Rate of inpatient admissions for patients receiving outpatient chemotherapy: 14.1 (12.7 to 15.7) · 2,191 cases, Jan 2024 – Dec 2024Better than the national rate — Postoperative respiratory failure rate: 4.08 (1.95 to 6.21) · 5,296 cases, Jul 2022 – Jun 2024Better than the national rate — Catheter Associated Urinary Tract Infections (ICU + select Wards): 0.317, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.446, Oct 2024 – Sep 2025Better than the national rate — SSI - Colon Surgery: 0.241, Oct 2024 – Sep 2025Better than the national rate — Ratio of unplanned hospital visits after hospital outpatient surgery: 0.7 (0.6 to 0.9) · 3,348 cases, Jan 2024 – Dec 2024
See every measure and the patient survey for Stanford Health Care
Behind the star rating — Deaths: 5 better, 3 the same, 0 worse of 8 measures. Safety: 3 better, 5 the same, 0 worse of 8 measures. Readmissions: 2 better, 5 the same, 4 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 5.31 (4.24 to 6.37) · 8,661 cases | Worse | Jul 2022 – Jun 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 14.1 (12.7 to 15.7) · 2,191 cases | Worse | Jan 2024 – Dec 2024 |
| Postoperative respiratory failure rateComplications and deaths | 4.08 (1.95 to 6.21) · 5,296 cases | Better | Jul 2022 – Jun 2024 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.317 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.446 | Better | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0.241 | Better | Oct 2024 – Sep 2025 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.7 (0.6 to 0.9) · 3,348 cases | Better | Jan 2024 – Dec 2024 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.06 (0.45 to 1.67) · 5,374 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.86 (0.72 to 1) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 166.09 (137.88 to 194.3) · 470 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 1.1 · 192 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 6.4 · 146 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 9.7 · 253 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 6.3 · 880 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 10.3 · 935 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 8.7 · 501 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 2.1 · 7,730 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.13 (0 to 0.27) · 20,799 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.28 (0.14 to 0.43) · 23,182 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 0.94 (0.2 to 1.68) · 5,694 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.36 (1.54 to 3.19) · 7,846 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 5.2 (3.76 to 6.64) · 5,603 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.38 (0.23 to 2.53) · 2,211 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.52 (0.21 to 0.83) · 19,915 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 3.6 · 416 cases | None | Apr 2023 – Mar 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.869 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.857 | No different | Oct 2024 – Sep 2025 |
| SSI - Abdominal HysterectomyInfections | 0.368 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 16.2 · 247 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 20.5 · 1,021 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 47.8 · 258 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -1.6 · 990 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 20.8 · 976 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 16.5 · 959 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 5.2 (4.4 to 6.2) · 2,191 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.1 · 425 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 9.6 · 158 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 19.6 · 183 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 12.7 (10.4 to 15.4) · 4,578 cases | No different | Jan 2022 – Dec 2024 |
What patients said (6,810 patients answered, 25% of those asked)
| Cleanliness | 4 |
| Nurse communication | 4 |
| Doctor communication | 4 |
| Communication about medicines | 3 |
| Discharge information | 4 |
| Overall hospital rating | 4 |
| Quietness | 2 |
| Recommend hospital | 5 |
| Room was "always" clean | 75% |
| Nurses "always" communicated well | 82% |
| Doctors "always" communicated well | 81% |
| Staff "always" explained | 63% |
| Yes, staff "did" give patients this information | 89% |
| Yes, staff "did" give patients information about help after discharge | 89% |
| Doctors "always" explained things so they could understand | 76% |
| Doctors "always" listened carefully | 80% |
| Doctors "always" treated them with courtesy and respect | 87% |
| Patients who gave a rating of "9" or "10" (high) | 79% |
| Staff "always" explained new medications | 76% |
| Nurses "always" explained things so they could understand | 77% |
| Nurses "always" listened carefully | 79% |
| Nurses "always" treated them with courtesy and respect | 88% |
| "Always" quiet at night | 53% |
| "YES", patients would definitely recommend the hospital | 83% |
| Staff "always" explained possible side effects | 50% |
| Yes, staff "did" give patients information about possible symptoms | 90% |
Original Medicare doctor bills
$7,163
Medicare paid this office $7,163 for 34 people. Most of that is long return visits and Botox.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Long return visit (40+ min) | 15 | $3,049 | $122 |
Who their Medicare patients are
34 Original Medicare patients in 2024. Average age 59 · Under 65 47% · Women 50% · Also on Medicaid 50% · Health risk score 1.22. At or below the middle of the specialty; the typical neurology clinician is at 1.61.
Conditions among them: High blood pressure 47%.
The office billed $28,695, Medicare allowed $9,828 and paid $7,163; for 78 services of 9 kinds.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 34 | 78 | 59 | 1.22 | $28,695 | $7,163 |
| 2023 | 37 | 78 | 60 | 1.31 | $32,558 | $7,639 |
| 2022 | 45 | 101 | 60 | 1.23 | $43,427 | $9,561 |
| 2021 | 40 | 121 | 60 | 1.32 | $46,443 | $11,458 |
| 2020 | 39 | 99 | 61 | 1.45 | $39,395 | $8,229 |
| 2019 | 38 | 117 | 59 | 1.44 | $24,075 | $8,253 |
| 2018 | 36 | 97 | 54 | 1.27 | $28,890 | $9,483 |
| 2017 | 34 | 75 | 54 | 1.33 | $22,962 | $7,440 |
| 2016 | 27 | 71 | 52 | 1.66 | $18,887 | $6,352 |
| 2015 | 33 | 62 | 54 | 1.85 | $15,381 | $5,005 |
| 2014 | 29 | 64 | 50 | 1.58 | $14,820 | $5,011 |
| 2013 | 26 | 48 | 46 | 1.52 | $10,311 | $3,015 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 2 services
| Long return visit (40+ min) | 24 | $5,082 | $124 |
| Return visit (30+ min) | 13 | $994 | $71 |
2022: 2 services
| Long return visit (40+ min) | 26 | $5,465 | $121 |
| Return visit (30+ min) | 13 | $1,145 | $82 |
2021: 2 services
| Long return visit (40+ min) | 30 | $7,089 | $122 |
| Return visit (30+ min) | 11 | $1,016 | $85 |
2020: 1 service
| Long return visit (40+ min) | 32 | $4,645 | $91 |
2019: 2 services
| Long return visit (40+ min) | 26 | $3,956 | $84 |
| Return visit (30+ min) | 14 | $789 | $56 |
2018: 3 services
| Long return visit (40+ min) | 26 | $3,307 | $77 |
| Return visit (30+ min) | 13 | $1,028 | $69 |
| Long return visit (40+ min) | 11 | $968 | $88 |
2017: 2 services
| Long return visit (40+ min) | 22 | $3,387 | $100 |
| Return visit (30+ min) | 18 | $1,150 | $50 |
2016: 2 services
| Return visit (30+ min) | 19 | $2,031 | $63 |
| Long return visit (40+ min) | 13 | $1,883 | $86 |
2015: 1 service
| Return visit (30+ min) | 25 | $2,514 | $64 |
2014: 1 service
| Return visit (30+ min) | 22 | $2,581 | $63 |
2013: 1 service
| Return visit (30+ min) | 21 | $2,330 | $63 |
Drugs they prescribed that Part D paid
$159,651
Pharmacies billed $159,651 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
Opioids were 0% of their Part D prescriptions (0 of 680) in 2024. At or below the middle of the specialty; the typical neurology clinician is at 0%.
606 generic and fewer than 11 brand-name prescriptions · $159,651 in drug cost.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Topamax | 14 | $30,102 | $2,150 |
| Trileptal | 16 | $29,339 | $1,834 |
| Lamictal | 12 | $8,190 | $682 |
| Lacosamide | 70 | $6,631 | $95 |
| Clobazam | 27 | $6,493 | $240 |
See all 24 drugs
| Topamax | 14 | $30,102 | $2,150 |
| Trileptal | 16 | $29,339 | $1,834 |
| Lamictal | 12 | $8,190 | $682 |
| Lacosamide | 70 | $6,631 | $95 |
| Clobazam | 27 | $6,493 | $240 |
| Lamotrigine Er | 16 | $4,883 | $305 |
| Carbamazepine Er | 37 | $3,649 | $99 |
| Topiramate | 19 | $3,501 | $184 |
| Levetiracetam | 67 | $2,759 | $41 |
| Keppra | 11 | $2,275 | $207 |
| Divalproex | 34 | $1,854 | $55 |
| Levetiracetam Er | 23 | $1,562 | $68 |
| Oxcarbazepine | 18 | $1,508 | $84 |
| Lamotrigine | 69 | $1,396 | $20 |
| Gabapentin | 13 | $1,092 | $84 |
| Carbamazepine | 11 | $799 | $73 |
| Divalproex Sodium Er | 26 | $476 | $18 |
| Lorazepam | 44 | $299 | $7 |
| Primidone | 17 | $229 | $13 |
| Phenytoin Sodium Extended | 12 | $210 | $18 |
| Clonazepam | 13 | $97 | $7 |
| Fluoxetine | 12 | $97 | $8 |
| Sertraline | 12 | $25 | $2 |
| Citalopram Hbr | 11 | $24 | $2 |
Year by year
| 2024 | 680 | 50 | 0% (0) | None | $159,651 |
| 2023 | 623 | 49 | 0% (0) | None | $233,464 |
| 2022 | 645 | 46 | 0% (0) | 16% | $408,922 |
| 2021 | 682 | 46 | 0% (0) | None | $455,127 |
| 2020 | 596 | 41 | 0% (0) | 27% | $443,226 |
| 2019 | 571 | 46 | 0% (0) | None | $466,679 |
| 2018 | 599 | 35 | None | 27% | $446,760 |
| 2017 | 574 | 35 | 0% (0) | 29% | $349,443 |
| 2016 | 595 | 32 | 0% (0) | None | $369,947 |
| 2015 | 575 | 32 | 0% (0) | None | $318,608 |
| 2014 | 604 | 29 | 0% (0) | None | $197,917 |
| 2013 | 471 | 27 | 0% (0) | 39% | $109,765 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 19 drugs
| Lacosamide | 60 | $33,866 | $564 |
| Topamax | 24 | $26,397 | $1,100 |
| Trileptal | 20 | $25,620 | $1,281 |
| Lamotrigine Er | 15 | $22,922 | $1,528 |
| Nayzilam | 16 | $19,579 | $1,224 |
| Lamictal | 12 | $15,933 | $1,328 |
| Clobazam | 41 | $11,451 | $279 |
| Divalproex | 20 | $3,079 | $154 |
| Lamotrigine | 52 | $3,065 | $59 |
| Carbamazepine Er | 40 | $3,018 | $75 |
| Levetiracetam | 60 | $2,631 | $44 |
| Levetiracetam Er | 15 | $1,856 | $124 |
| Primidone | 26 | $1,372 | $53 |
| Carbamazepine | 16 | $1,222 | $76 |
| Gabapentin | 16 | $736 | $46 |
| Oxcarbazepine | 14 | $466 | $33 |
| Lorazepam | 36 | $360 | $10 |
| Clonazepam | 25 | $283 | $11 |
| Venlafaxine Hcl Er | 12 | $134 | $11 |
2022: 20 drugs
| Everolimus | 11 | $162,983 | $14,817 |
| Vimpat | 27 | $41,713 | $1,545 |
| Lamictal | 13 | $27,710 | $2,132 |
| Trileptal | 16 | $24,001 | $1,500 |
| Lacosamide | 24 | $19,899 | $829 |
| Clobazam | 37 | $11,843 | $320 |
| Levetiracetam | 91 | $2,722 | $30 |
| Carbamazepine Er | 37 | $2,514 | $68 |
| Lamotrigine | 67 | $2,011 | $30 |
| Oxcarbazepine | 17 | $2,011 | $118 |
| Divalproex | 21 | $1,702 | $81 |
| Carbamazepine | 32 | $1,488 | $46 |
| Levetiracetam Er | 14 | $1,476 | $105 |
| Primidone | 39 | $984 | $25 |
| Phenytoin Sodium Extended | 12 | $830 | $69 |
| Divalproex Sodium Er | 19 | $493 | $26 |
| Gabapentin | 17 | $363 | $21 |
| Lorazepam | 39 | $267 | $7 |
| Clonazepam | 14 | $180 | $13 |
| Venlafaxine Hcl Er | 12 | $163 | $14 |
2021: 18 drugs
| Afinitor | 13 | $215,677 | $16,591 |
| Vimpat | 63 | $102,875 | $1,633 |
| Lamictal | 13 | $19,940 | $1,534 |
| Fycompa | 13 | $14,372 | $1,106 |
| Levetiracetam | 102 | $5,869 | $58 |
| Carbamazepine Er | 50 | $4,282 | $86 |
| Divalproex Sodium Er | 19 | $2,312 | $122 |
| Lamotrigine | 69 | $2,130 | $31 |
| Levetiracetam Er | 21 | $2,005 | $95 |
| Carbamazepine | 18 | $1,668 | $93 |
| Gabapentin | 33 | $1,556 | $47 |
| Divalproex | 22 | $1,379 | $63 |
| Clobazam | 24 | $1,094 | $46 |
| Primidone | 29 | $935 | $32 |
| Clonazepam | 35 | $508 | $15 |
| Lorazepam | 36 | $236 | $7 |
| Fluoxetine | 11 | $193 | $18 |
| Propranolol | 12 | $85 | $7 |
2020: 16 drugs
| Afinitor | 13 | $215,677 | $16,591 |
| Vimpat | 46 | $67,777 | $1,473 |
| Lamictal Xr | 12 | $60,864 | $5,072 |
| Lamictal | 27 | $41,138 | $1,524 |
| Lamotrigine | 72 | $4,268 | $59 |
| Levetiracetam | 88 | $3,838 | $44 |
| Carbamazepine Er | 44 | $3,735 | $85 |
| Carbatrol | 12 | $1,972 | $164 |
| Levetiracetam Er | 14 | $1,368 | $98 |
| Clobazam | 22 | $1,352 | $61 |
| Primidone | 27 | $921 | $34 |
| Clonazepam | 31 | $741 | $24 |
| Gabapentin | 22 | $699 | $32 |
| Lorazepam | 34 | $297 | $9 |
| Phenobarbital | 11 | $211 | $19 |
| Escitalopram | 17 | $112 | $7 |
2019: 15 drugs
| Afinitor | 13 | $214,448 | $16,496 |
| Vimpat | 71 | $81,476 | $1,148 |
| Lamictal Xr | 14 | $39,328 | $2,809 |
| Lamictal | 24 | $31,209 | $1,300 |
| Trileptal | 12 | $19,239 | $1,603 |
| Lamotrigine Er | 17 | $6,812 | $401 |
| Carbamazepine Er | 27 | $2,877 | $107 |
| Divalproex Sodium Er | 21 | $2,517 | $120 |
| Gabapentin | 29 | $2,372 | $82 |
| Levetiracetam | 69 | $2,259 | $33 |
| Lamotrigine | 72 | $1,845 | $26 |
| Levetiracetam Er | 19 | $1,799 | $95 |
| Primidone | 26 | $761 | $29 |
| Lorazepam | 22 | $190 | $9 |
| Escitalopram | 12 | $126 | $10 |
2018: 16 drugs
| Afinitor | 13 | $197,347 | $15,181 |
| Vimpat | 66 | $74,019 | $1,121 |
| Banzel | 11 | $52,653 | $4,787 |
| Neurontin | 12 | $24,412 | $2,034 |
| Lamotrigine Er | 48 | $17,308 | $361 |
| Divalproex Sodium Er | 42 | $7,946 | $189 |
| Carbamazepine Er | 25 | $3,771 | $151 |
| Levetiracetam | 72 | $2,301 | $32 |
| Levetiracetam Er | 21 | $1,768 | $84 |
| Carbatrol | 12 | $1,360 | $113 |
| Lamotrigine | 43 | $772 | $18 |
| Primidone | 46 | $627 | $14 |
| Clonazepam | 27 | $230 | $9 |
| Citalopram Hbr | 14 | $147 | $11 |
| Gabapentin | 17 | $125 | $7 |
| Lorazepam | 19 | $82 | $4 |
2017: 15 drugs
| Afinitor | 12 | $156,051 | $13,004 |
| Vimpat | 65 | $70,814 | $1,089 |
| Banzel | 17 | $46,233 | $2,720 |
| Lamotrigine Er | 28 | $21,159 | $756 |
| Divalproex Sodium Er | 53 | $6,526 | $123 |
| Levetiracetam | 82 | $2,053 | $25 |
| Carbamazepine Er | 22 | $1,820 | $83 |
| Carbatrol | 12 | $1,550 | $129 |
| Lamotrigine | 59 | $1,210 | $21 |
| Levetiracetam Er | 14 | $821 | $59 |
| Primidone | 28 | $341 | $12 |
| Citalopram Hbr | 21 | $70 | $3 |
| Gabapentin | 15 | $66 | $4 |
| Clonazepam | 11 | $61 | $6 |
| Lorazepam | 14 | $32 | $2 |
2016: 17 drugs
| Afinitor | 13 | $157,569 | $12,121 |
| Vimpat | 75 | $59,560 | $794 |
| Banzel | 24 | $45,596 | $1,900 |
| Lamotrigine Er | 31 | $33,328 | $1,075 |
| Neurontin | 11 | $17,443 | $1,586 |
| Trileptal | 13 | $16,023 | $1,233 |
| Divalproex Sodium Er | 68 | $11,624 | $171 |
| Fycompa | 11 | $8,824 | $802 |
| Carbamazepine Er | 49 | $3,843 | $78 |
| Depakote Er | 12 | $3,604 | $300 |
| Carbatrol | 16 | $2,412 | $151 |
| Lamotrigine | 50 | $1,743 | $35 |
| Levetiracetam | 76 | $1,341 | $18 |
| Olanzapine Odt | 13 | $1,266 | $97 |
| Clonazepam | 23 | $689 | $30 |
| Divalproex | 22 | $432 | $20 |
| Zonisamide | 21 | $144 | $7 |
2015: 14 drugs
| Vimpat | 69 | $61,635 | $893 |
| Banzel | 25 | $36,861 | $1,474 |
| Lamotrigine Er | 36 | $34,239 | $951 |
| Divalproex Sodium Er | 60 | $15,055 | $251 |
| Neurontin | 11 | $12,067 | $1,097 |
| Trileptal | 11 | $11,759 | $1,069 |
| Carbatrol | 20 | $2,170 | $108 |
| Carbamazepine Er | 31 | $2,038 | $66 |
| Levetiracetam | 76 | $1,516 | $20 |
| Olanzapine Odt | 12 | $1,279 | $107 |
| Lamotrigine | 50 | $612 | $12 |
| Clonazepam | 37 | $368 | $10 |
| Olanzapine | 11 | $69 | $6 |
| Lorazepam | 11 | $47 | $4 |
2014: 17 drugs
| Vimpat | 89 | $73,449 | $825 |
| Banzel | 21 | $24,583 | $1,171 |
| Lamotrigine Er | 21 | $23,947 | $1,140 |
| Divalproex Sodium Er | 71 | $16,999 | $239 |
| Trileptal | 13 | $11,986 | $922 |
| Neurontin | 11 | $10,265 | $933 |
| Carbatrol | 17 | $3,158 | $186 |
| Peganone | 13 | $2,136 | $164 |
| Levetiracetam | 67 | $1,861 | $28 |
| Carbamazepine | 23 | $1,749 | $76 |
| Methylphenidate Er | 11 | $1,695 | $154 |
| Lamotrigine | 70 | $1,562 | $22 |
| Carbamazepine Er | 11 | $1,024 | $93 |
| Olanzapine | 11 | $659 | $60 |
| Phenytoin Sodium Extended | 15 | $549 | $37 |
| Methylphenidate | 11 | $395 | $36 |
| Clonazepam | 47 | $364 | $8 |
2013: 15 drugs
| Vimpat | 78 | $42,684 | $547 |
| Trileptal | 11 | $8,932 | $812 |
| Carbatrol | 20 | $4,821 | $241 |
| Divalproex Sodium Er | 47 | $4,691 | $100 |
| Olanzapine Odt | 12 | $2,402 | $200 |
| Peganone | 12 | $1,958 | $163 |
| Carbamazepine Xr | 16 | $1,562 | $98 |
| Methylphenidate Er | 11 | $1,490 | $135 |
| Topiramate | 33 | $846 | $26 |
| Levetiracetam | 27 | $834 | $31 |
| Lamotrigine | 41 | $824 | $20 |
| Methylphenidate | 11 | $245 | $22 |
| Carbamazepine | 18 | $213 | $12 |
| Clonazepam | 35 | $212 | $6 |
| Olanzapine | 13 | $207 | $16 |
Money from drug and device companies
$13,025 in 2022
| 2022 | 1 | 1 | $13,025 | $13,025 |
| 2021 | 1 | 2 | $3,622 | $3,622 |
| 2019 | 1 | 2 | None | $100 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
NeuroPace, Inc.
$4,200
Held by this doctor · 2020, 2019 · Restricted Stock
Published ownership or investment in a drug or device company. This is not proof that care is biased.
A payment is not proof that care is biased.
| Eisai | None | $13,025 | 1 payment
|
See the published payment
| Eisai | Consulting · 2022-01-06 | None | $13,025 |
See earlier years (2021, 2019)
2021: $3,622
| Eisai | None | $3,622 | 2 payments
|
2019: $100
| Zimmer Biomet Holdings | Rosa | $100 | 2 payments
|
Checkups this office reported
Medicare did not publish checkup rates for this clinician.
- Medicare’s overall office score
- 76.5 / 100
- Scores the office’s reporting and systems. It is not a grade for how the doctor treats you.
Professional record
- NPI
- 1174688980
- Licence
- CA G068498
- Trained
- Stanford University School of Medicine, 1984
- Group
- Stanford Health Care
- Video visits
- Lists video visits
- Gender
- Female
More record details
- Sole proprietor
- No
- Taxonomy
- Federal specialty code 2084E0001X (2084E0001X); Neurology (2084N0400X); Federal specialty code 2084N0600X (2084N0600X)
- Mailing address
- 300 Pasteur Dr, Stanford, CA, 94305
- NPI first listed
- 2006-12-22
- NPI last updated
- 2023-11-10
- NPI record certified
- 2023-11-10
This is when the NPI record was last certified, not a medical board exam.